🚨 LANDMARK IP CASES IN INDIA | EPISODE 14 🇮🇳
Welcome back to Episode 14 of our series decoding the jurisprudence shaping India’s intellectual property landscape.
If you are a Patent Analyst navigating the complex boundaries of subject-matter eligibility, or an aspirant gearing up for the Patent Agent Exam on Jan 10, 2027, mastering Section 3 of the Indian Patents Act—specifically what constitutes a non-patentable invention—is non-negotiable.
In Episode 13, we tackled "Prior Publication."
Today, let's dive into the absolute foundational case for Biotech, Agriculture, and Section 3(j):
🏛️ Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) - Supreme Court of India
Let’s break down the "Subject-Matter Eligibility" battle:
The plaintiff (Monsanto) held a patent for their Bt cotton technology—specifically a Nucleic Acid Sequence (NAS) containing the Cry2Ab gene that made seeds resistant to bollworms. When disputes arose over trait fees, they sued the defendant (Nuziveedu) for infringement.
The defendant immediately counter-attacked, claiming the patent was invalid under Section 3(j) of the Patents Act, which states that "plants and animals... including seeds, varieties and species... are not inventions." They argued that once the genetic sequence is inserted into a plant, it becomes an inherent biological part of the seed and is therefore unpatentable.
The core legal question: Does a patented, man-made DNA sequence lose its patent protection and fall under the exclusions of Section 3(j) the moment it is integrated into a plant?
While a Division Bench of the Delhi High Court initially shocked the industry by revoking the patent summarily, the Supreme Court delivered a masterclass ruling:
The Supreme Court set aside the revocation, holding that highly complex invalidity claims—like whether a DNA construct physically becomes a "plant part" under Section 3(j)—cannot be decided in a summary proceeding. It requires rigorous expert evidence and a full trial to understand the true scientific and technical scope of the claims.
💡 Pro Tip for Analysts & Aspirants: When drafting claims or mapping patents in the biotech space for India, the line between an "inventive isolated DNA sequence" (patentable) and a "plant variety" (non-patentable under Sec 3(j)) is razor-thin.
Precision in technical drafting is everything!
What are your thoughts on protecting deep-tech biotech and agritech innovations under Indian IP law?
Udeyanju Kumar
Bullseye Intelligent R&D Solutions
#PatentLaw #IntellectualProperty #PatentSearch #PatentAgentExam #BiotechPatents #IndianLaw #BullseyeIntelligentSolutions #Episode14
10 Agosto 2026 à 02h21
Ver en LinkedIn →
